Hepatitis C virus (HCV) infections are the major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma worldwide. Both spontaneous and treatment-induced clearance of HCV depend on genetic variation within the interferon-lambda locus, but until now no clear causal relationship has been established. Here we demonstrate that an amino-acid substitution in the IFNl4 protein changing a proline at position 70 to a serine (P70S) substantially alters its antiviral activity. Patients harbouring the impaired IFNl4-S70 variant display lower interferon-stimulated gene (ISG) expression levels, better treatment response rates and better spontaneous clearance rates, compared with patients coding for the fully active IFNl4-P70 variant. Altogether, these data provide evidence supporting a role for the active IFNl4 protein as the driver of high hepatic ISG expression as well as the cause of poor HCV clearance.
H epatitis C virus (HCV) infections are the major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma worldwide 1 . HCV is parenterally transmitted, mainly due to injection drug use, unsafe transfusions and therapeutic injections. In 70-80% of those infected, the virus persists and the infection becomes chronic, and eventually requires antiviral therapy. During the past 25 years, recombinant interferon-alpha (IFNa) has been an essential component of HCV treatment 2 , however, the recent availability of potent direct-acting antiviral agents (DAA) is changing the therapeutic options.
The overall sustained virological response (SVR) rate achieved using a combination of pegylated IFNa (pegIFNa) and ribavirin is only about 50%, and the prognosis for individual patients strongly depends on their genetic background. In particular, the genetic variation within the IFNL3 (IL28B) locus is crucial in determining the treatment outcome [3] [4] [5] [6] . Furthermore, the response to IFN-based therapy depends strongly on the expression of IFN-stimulated genes (ISGs) in patients before the initiation of treatment [7] [8] [9] and variations near the IFNL3 (IL28B) locus correlate with the ISG induction in the liver [10] [11] [12] . Somewhat paradoxically, patients showing increased pretreatment expression of ISG in the liver respond poorly to pegIFNa/ribavirin therapy [7] [8] [9] . However, the mechanism responsible for driving ISG induction in the HCV-infected liver has remained elusive. Roughly, a quarter of HCV-infected individuals clear the virus spontaneously, this largely happens during the acute phase of the infection. Somewhat surprisingly, the genetic variations near the IFNL3 (IL28B) locus are also strongly associated with spontaneous clearance of HCV infection 13, 14 . That points towards a pivotal role for IFNls in HCV clearance and a possible influence of IFNls on the adaptive immune response that is generated during the acute phase of HCV infection.
A recent key discovery identified the IFNL4 gene and showed that a polymorphism (rs368234815), which causes the disruption of the IFNL4 reading frame, correlates with a substantially better treatment response 15, 16 as well as better spontaneous clearance rate 13 . Thus, patients having a nonfunctional IFNL4 gene are more likely to clear the HCV infection. This suggests that the production of IFNl4 in carriers of the ancestral rs368234815 DG allele is responsible for the transcriptional activation of ISGs, thus providing a molecular link between the genotype and clearance of HCV. This hypothesis is supported by the recent finding that recombinant IFNl4 protein strongly stimulates Jak-STAT signalling and ISG induction through binding to the IFNl receptor 17 . Here we describe a strong link between a reduced antiviral activity of the IFNl4 protein and a reduced hepatic ISG expression as well as an improved HCV clearance.
Results
Substitution at position 70 impairs the activity of IFNk4. Three non-synonymous single-nucleotide polymorphisms (SNPs) in the IFNL4 gene were previously described but not characterized 15, 18 , those being C17Y (rs73555604), R60P (rs142981501) and P70S (rs117648444). We noted that a P70S substitution (rs117648444) could potentially alter the activity of the protein, in addition this has a minor allele frequency (MAF) in Caucasian of 0.11 (HapMap), whereas the two other have 0 and 0.025, respectively. Proline 70 is located outside of the assumed receptor binding site 19, 20 , but structural modelling suggests that P70 is important for the stability of the IFNl4 protein 17 . In the following, the two variants of IFNl4 will be denoted as IFNl4-P70 and IFNl4-S70, respectively.
We expressed the mature form of both variants in Escherichia coli, purified them (Fig. 1a) and tested their activity. The IFNl4-S70 variant induced significantly lower levels of both MX1 and IFIT1 transcription in human hepatocellular carcinoma cells (HepG2; Fig. 1b) . Next, a dose-response experiment was performed in human embryonic kidney cells (HEK293) transfected with an IFN-responsive firefly luciferase reporter construct, a Renilla luciferase construct for normalization and a construct expressing the IFNlR1 receptor chain (Fig. 1c) . We obtained half-maximal effective concentration (EC 50 ) values of 4.0 ng ml À 1 for IFNl4-P70 and 9.5 ng ml À 1 for IFNl4-S70. This difference was significant using 99% confidence intervals (Supplementary Table 1 ). Finally, we performed an antiviral assay using encephalomyocarditis virus (EMCV) infection in HepG2 cells ( Fig. 1d; Supplementary Table 1 ). Here we saw a significant shift in the (EC 50 ) values from 0.2 ng ml À 1 for the IFNl4-P70 to 1.4 ng ml À 1 for IFNl4-S70. Thus, the IFNl4-S70 variant is substantially less active than the IFNl4-P70 variant.
rs117648444 A is an independent predictor of HCV clearance. If the active IFNl4 protein is the causative agent responsible for the poor HCV clearance in patients, then one would expect the P70S substitution (rs117648444) to influence the ability of patients to clear HCV. Thus, we evaluated the role of the rs117648444 A (IFNl4-S70, MAF ¼ 0.11) and rs368234815 DG (expressing IFNl4, MAF ¼ 0.35) polymorphisms in HCV clearance in a cohort of 574 chronically infected patients who underwent pegIFNa/ribavirin treatment, as well as in 122 patients with spontaneous clearance (Table 1; Supplementary Tables 2 and 3) . We analysed the independent contribution of each polymorphism, by including both of them in the same logistic regression model. As expected, rs368234815 DG was associated with a lower SVR rate (odds ratio (OR) ¼ 0.23, 95% confidence interval (CI) 0.15-0.35, P ¼ 1.5E-11, dominant mode of inheritance), while rs117648444 A (IFNl4-S70) was associated with a higher SVR rate (OR ¼ 1.66, 95% CI 1.08-2.55, P ¼ 0.02). Thus, both rs117648444 A and rs368234815 DG are independent predictors of treatment-induced HCV clearance. A similar trend was observed for spontaneous clearance (OR ¼ 0.21, 95% CI 0.13-0.34, P ¼ 4.4E-10 for rs368234815 DG ; OR¼ 1.63, 95% CI 0.88-3.02, P ¼ 0.12 for rs117648444 A ; Table 1 ).
Stratification of patients according to IFNk4 functionality.
A haplotype analysis was performed to understand the co-inheritance pattern of rs368234815 and rs117648444, which would help to clarify the role of the activity of IFNl4 in HCV clearance. This analysis showed that 95% of the chromosomes are composed of three main haplotypes: TT G (65%), which is predicted not to produce IFNl4, DG G (22%), which is predicted to produce the IFNl4-P70 variant, and DG A, which is predicted to express the IFNl4-S70 variant (11%; Supplementary Table 4 ). The frequency distribution in our study population is in accordance with previously published data 15, 18 . The fourth haplotype TT A, which does not express IFNl4, was found in only 0.5% of the chromosomes, and is grouped with the TT G haplotype in the subsequent analyses. The DG G haplotype (IFNl4-P70, R 2 ¼ 0.74) was in linkage disequilibrium (LD) with the SNP rs8099917, which emerged as the top hit for spontaneous or treatment-induced HCV clearance in three out of four initial hepatitis C genome-wide association studies (GWAS; Table 2 ).
The haplotypic combinations produced eight diplotypes (Table 3) , which can be classified into three main functional groups according to their ability to produce IFNl4-P70 or IFNl4-S70. The first group consists of patients not producing IFNl4 (N ¼ 283). The second group contains diplotypes that exclusively code for IFNl4-S70 (N ¼ 114). The third group consists of those that give rise to the fully functional IFNl4-P70 (N ¼ 299). This group is composed of 270 samples with the TT G/DG G and the DG G/DG G diplotype producing only the IFNl4-P70 variant, and 29 samples with the DG A/DG G diplotype producing both variants of IFNl4.
IFNk4-S70 associates with a better clearance rate of HCV. We analysed the response to treatment in patients producing IFNl4-S70 alone and those producing IFNl4-P70 alone grouped with IFNL4-P70/S70 compared with those not producing IFNl4. Patients not producing IFNl4 had an overall SVR rate of 81% after treatment with pegIFNa/ribavirin compared with only 47% among those who produced the IFNl4-P70 or P70/S70 variants (OR ¼ 0.21, 95% CI 0.14-0.33, P ¼ 8.3E À 13; Table 1 ; Fig. 2a) . We then excluded patients not producing IFNl4 to specifically assess the role of the P70S substitution. Interestingly, patients who produced exclusively the IFNl4-S70 had a much higher response rate (69%) compared with those producing the IFNl4-P70 or P70/ S70 variants (OR ¼ 2.52, 95% CI 1.55-4.13, P ¼ 0.0002). This clearly shows that the chance of clearing the virus is highest in the group of patients not expressing IFNl4, slightly lower in those expressing the impaired IFNl4-S70 variant and the worst in those expressing the fully active IFNl4-P70 form. The differences in SVR rates between all three groups were significant. This agrees well with the biochemical data, which show that IFNl4-S70 has an impaired but still clearly measurable activity. These associations were still significant in a multivariate model after adjustment for relevant covariates (Table 1) . The association was similar, although less significant, when the analysis was restricted to patients infected with HCV genotype 1 (Supplementary Table 5) .
Roughly, a quarter of all HCV-infected individuals spontaneously clear the HCV infection, mainly during the acute phase of the infection by mounting an efficient immune response to the virus 21 . We investigated whether the level of IFNl4 activity was associated with the spontaneous clearance. Similarly to what was observed for the treatment-induced clearance, the proportion of patients with spontaneous clearance was 29% among patients unable to produce IFNl4, 7% among those producing the IFNl4-P70 or P70/S70 variants and 15% among those producing exclusively IFNl4-S70 (Table 1 ; Fig. 2b ).
IFNk4-P70 is associated with high ISG expression. We have previously shown that the quantification of the expression of four ISGs (IFI27, ISG15, RSAD2 and HTATIP2) in liver biopsy samples allows one to predict the response to pegIFNa/ribavirin treatment 10 . This 4-gene classifier was obtained through a multivariate analysis using decision tree ensembles in the form of a random forest classifier and is expressed as the probability of obtaining a sustained virological response (pSVR). The pSVR value contains the collective information from the four genes measured and is inversely correlated with ISG expression in the liver 10 . In the present work, the 4-gene classifier was used as a surrogate marker for the overall ISG expression in 104 liver biopsies from patients with chronic hepatitis C. The biopsies were then genotyped for the IFNl4 variants and classified into the three groups corresponding to the genomic analysis described above. In an analysis including all viral genotypes, the median ARTICLE pSVR was 85% in group 1 (no IFNl4, N ¼ 39), 72% in group 2 (functionally defective IFNl4-S70, N ¼ 12) and 46% in group 3 (fully functional IFNl4-P70, N ¼ 53). The difference between groups 1 and 3, but not between 1 and 2, was statistically significant (Fig. 3a) . The results did not change when the analysis was restricted to patients infected with HCV genotype 1 (Fig. 3b) . Thus, there is a clear correlation between the activity of the IFNl4 protein and the hepatic ISG expression level.
Discussion
Because IFNl4-P70, but not the functionally defective IFNl4-S70, is associated with a strong induction of ISG expression (and therefore a low pSVR), we conclude that IFNl4 is the major component of the molecular mechanisms responsible for hepatic ISG expression in patients with HCV infections. Sustained signalling through the IFNl receptor can inhibit subsequent responses to type I IFN through the induction of the USP18 protein 22, 23 . Therefore, prolonged IFNl signalling caused by the IFNl4 protein is obviously inhibitory to subsequent treatment with pegIFNa/ribavirin. Interestingly, previous work has observed an association between both SNP rs12979860 (ref. 14) (situated in the IFNL4 intronic region) and rs368234815 (ref. 13) (the DG allele determining IFNl4 expression) and the rate of spontaneous clearance of HCV. We observed a clear correlation between the activity of IFNl4 and the spontaneous clearance rate.
Patients producing the impaired IFNl4-S70 had a 15% chance of spontaneous clearance compared with a 7% clearance rate among patient coding for the active IFNl4-P70 variant. Among patients homozygous for the rs368234815 TT allele (major allele, causing a IFNL4 frame shift mutation), the clearance rate was increased to 29%. As the majority of spontaneous clearance occurs during the acute phase of HCV infection, the IFNl4 protein must influence the early phase of an HCV infection in a way that is favouring development of a chronic infection and thus impairing spontaneous clearance. We speculate that the IFNl4 protein can influence adaptive immunity, which is established during the acute phase, and that this is a long-lasting influence. Our data link the active form of IFNl4 (IFNl4-P70) to high ISG expression and thus to low level of viral replication, which somewhat counterintuitively leads to poor treatment response. We suggest that IFNl4-P70-driven ISG expression causes lower level of viral replication, which in turn leads to an inefficient adaptive immune response, and that this is the base of poor HCV clearance. This is supported by a recent study showing an association between the rs368234815 DG allele (IFNl4 expression) and activity level of T cells 24 . Furthermore, our findings are supported by a recent paper, showing that patients carrying the IFNl4-S70-coding allele exhibit a faster decline in HCV RNA levels at week 4 of treatment 25 . Combining rs368234815 and rs117648444 polymorphisms, it is possible to stratify patients into three groups, with the highest cure rates in patients not producing IFNl4, intermediate cure rates among those producing the IFNl4-S70 variant and the lowest cure rates among those producing the IFNl4-P70 variant. Furthermore, there is an excellent agreement between the predicted response rate (pSVR) obtained by measuring ISG expression in liver biopsies and the experientially observed SVR, once patients are stratified according to the three groups defined above. In our cohort, 26% of the patients being able to express IFNl4 harbour only the IFNl4-S70 variant, and thus have a prognosis that is almost as good as those not producing IFNl4. Thus, by combining both polymorphisms, it is possible to substantially improve the accuracy of the predicted response rate before treatment. In addition, we can clarify a discrepancy that has puzzled the field. The rs368234815 polymorphism that determines the ability to express IFNl4 is not in LD with rs8099917, which was found as a good SVR predictor in three out of four of the initial GWAS studies [3] [4] [5] [6] . This was unexpected and did initially argue against the IFNl4 protein as the causative agent; however, it is now clear that the minor allele of rs8099917 specifically tags the haplotype producing the IFNl4-P70 variant, which we have shown to be associated with the poorest clearance rates.
One may argue that the use of genetic markers may become obsolete with the advent of direct-acting antiviral agents (DAAs), due to their high cure rates [26] [27] [28] . Nevertheless, the role of IFNL3/ IFNL4 polymorphisms has been convincingly demonstrated in the first generation DAA treatment regimes. The SOUND-C2 trial assessing the combination of faldaprevir and deleobuvir with or without ribavirin showed a significantly higher SVR rates for patients homozygous for the favourable allele of rs12979860 (CC), clearly demonstrating a role for IFNL genotype in IFN-free DAA treatment regimens 29 . Thus, in mechanistic term, the role of the IFNL genotype is not restricted to IFN-based therapies, but do influence DAA-based treatments. However, recent development in DAA combination therapies using drugs with a substantially improved potency has pushed SVR above 90% for all patients, regardless of their IFNL genotype. With cure rates, this high knowledge of the genotype will have little impact on patients' choices of treatment. However, there are several clinical as well as scientific reasons to pursue a deeper understanding of how IFNL genotype impact viral clearance. Several recent studies show that rs368234815 influences the response kinetics to DAA 28, 30 ; however, the role of rs117648444 in DAA treatment has not yet been investigated. This suggests that patients not expressing IFNl4 can receive a shortened DAA treatment and possibly also reduced doses. There will be both obvious benefits for patients and substantial cost reduction by a targeted shortening of therapy in patients with favourable IFNL genotype. Our study clearly shows that the decision should be based on a dual genotyping of rs117648444 and rs368234815.
The expression of active IFNl4 influences both IFN-based and IFN-free treatment of chronic HCV infections, as well as strongly influences the spontaneous clearance rate. These observations point towards a fundamental role of active IFNl4 in facilitating and maintaining a chronic HCV infection. A recent study showed that rs368234815 also influenced susceptibility to cytomegalovirus retinitis among HIV-infected patients 31 , suggesting that the IFNl4 protein might play detrimental role in several different chronic viral infections. Thus, we believe that the activity of IFNl4 could play an important role in multiple chronic viral infections by a mechanism similar to that observed in hepatitis C.
Methods
Protein expression and purification. BL21 (DE3) E. coli cells transformed with the plasmids were grown at 37°C in Luria Bertani medium containing 100 mg ml À 1 ampicillin and 100 ml antifoam A concentrate (Sigma-Aldrich, catalogue number A5633) under continuous shaking until an OD 600 of 0.8-1. Protein expression was induced by adding 1 mM isopropyl-b-D-thiogalactopyranoside and incubating for another 4 h at 37°C. Refolding and purification were performed as previously described 32 . The His-tag was removed by the tobacco etch virus (TEV) protease cleavage after the refolding was completed. The TEV was removed during the subsequent cation exchange chromatography using a HiTrap SP FF column. The TEV cleavage was omitted for IFNl3. It is worth noting that the yield of IFNl4 protein is low with 1-2 mg of purified protein from 12 l E. coli culture. We did not note any consistent differences in the expression levels between IFNl4-P70 and IFNl-S70.
Plasmids. The IFNl4-S70 constructs were generated by site-directed mutagenesis using PfuUltra II Fusion HS DNA polymerase according to the manufacturer's instructions (Agilent). For the mammalian cell expression, pEF2-IFNl4-S70-FLAG was generated on pEF2-IFNl4-P70-FLAG template using forward 5 0 -CCGCGGAG AATCCCTCCTGGGGC-3 0 and reverse 5 0 -GCCCCAGGAGGGATTCTCCGCGG-3 0 primers. For the expression in E. coli, pET15b-IFNl4-S70 was generated on pET15b-IFNl4-P70 construct using forward 5 0 -GCTGCTCGGACGAGGCGAAT CACGACGCGGACG-3 0 and reverse 5 0 -CGTCCGCGTCGTGATTCGCCTCGTC CGAGCAGC-3 0 primers. The following PCR programme was used: (1) 95°C for 30 s; (2) 16 cycles of 95°C for 30 s, 65°C for 1 min and 72°C for 4 min; and (3) 72°C for 10 min.
Cell culture. Unless otherwise stated, all cells were grown in Dulbecco's modified Eagle's medium (DMEM), which was supplemented with 10% fetal bovine serum, 100 U ml À 1 penicillin and 100 mg ml Activity assay in HEK293 cells. HEK293 cells were seeded at a density of 7.5 Â 10 4 cells per well in a 48-well plate and left to rest for 24 h. After 24 h, the cells were transfected with the pEF2 plasmid encoding IFNlR1, firefly luciferase under the control of the Mx1 promoter 33 and Renilla luciferase under the control of the b-actin promoter. Eighteen hours post-transfection, cells were induced in quadruplicates with eight dilutions of IFNl4-P70 and IFNl4-S70 in the concentration range covering 0.006-100 ng ml À 1 for 24 h. After 24 h, the cells were washed with PBS and lysed with Passive Lysis Buffer (Promega). The lysates were spun down at 10,000 g for 2 min at 4°C, and the cleared lysates were used for the measurement of luciferase activity (Dual-Luciferase Reporter Assay System, Promega). EC 50 , efficacy and exponential slope values were estimated in GraphPad prism version 5.04 by fitting a sigmoidal equation to the plot. The equation used for fitting was: firefly/Renilla ratio ¼ baseline þ (efficacy À baseline)/ (1 þ 10 ((logEC 50 À X) Â Slope) ). Values for baseline were restrained to zero.
Real-time quantitative PCR. HepG2 cells were seeded at a density of 2 Â 10 5 cells per well in 12-well plates, and after 24 h, fresh media were added with the indicated IFNs in quadruplicates. After 4 h of incubation, cells were lysed and RNA was purified using an extraction kit (Omega) according to the manufacturer's instructions. Complementary DNA synthesis was performed with 1 mg RNA using RevertAid reverse transcriptase and random hexamer primer according to the manufacturer's instructions (Thermo Scientific). The cDNA obtained from cells was quantified by real-time quantitative PCR using SYBR Green I (Roche) on Roche LightCycler 480 II. The following primers were used: GAPDH, forward in the concentration range covering 0.008-200 ng ml À 1 for 24 h. The cells were then infected with EMCV (VR-129B strain) at a multiplicity of infection of 0.45. After 24 h, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Sigma Aldrich) was added at a concentration of 0.8 mg ml À 1 in DMEM, and the cells were incubated for additional 4 h. The cells were dissolved in dimethyl sulfoxide (Sigma-Aldrich). MTT conversion was determined by measurement of the A 600 . Measured absorptions in the IFN wells (Abs) were normalized as a percent of the cell control (CC) with the virus control (VC) subtracted, using the following equation: normalized cell survival (NCS) ¼ (Abs À VC/(CC À VC)) Â 100 to allow activity comparisons between plates. EC 50 , efficacy and exponential slope values were estimated as described in the section entitled 'Activity assay in HEK293 cells'.
Liver biopsies. Liver biopsies from patients (n ¼ 104) were obtained in the outpatient clinic of the Division of Gastroenterology and Hepatology, University Hospital Basel, Switzerland. Parts of the biopsy material that were not needed for routine histopathology were used for research purposes after obtaining written informed consent. The use of biopsy material for this project was approved by the Ethikkommission Nordwest-und Zentralschweiz, Basel, Switzerland. Serum HCV RNA was quantified using the Cobas AmpliPrep/COBAS TaqMan HCV Test and the Cobas Amplicor Monitor from Roche Molecular Systems (Basel, Switzerland).
Total RNA and genomic DNA were isolated from liver biopsies using Trizol reagent (Invitrogen, Basel, Switzerland) and DNeasy Blood & Tissue Kit (Qiagen, Hombrechtikon, Switzerland) according to the manufacturer's instructions. A fragment of 850 base pair covering rs368234815 and rs117648444 was amplified with the Expand High Fidelity PCR System (Roche) using forward 5 0 -ACTGTGTG TGCTGTGCCTTC-3 0 and reverse 5 0 -GGACGAGAGGGCGTTAGAG-3 0 primers. The product was purified on a column using NucleoSpin Gel and PCR clean-up (Macherey-Nagel AG, Oensingen, Switzerland) according to the manufacturer's instructions and then sequenced (Microsynth AG, Balgach, Switzerland).
pSVR was calculated using the 4-classifier genes as described previously 10 . Statistical analysis was performed using Prism6 (GraphPad software. La Jolla, CA, USA).
Genetic association study. Samples from patients with written informed consent for genetic studies and available DNA were collected from the Swiss Hepatitis C Cohort Study (SCCS), a multicenter study of HCV-infected patients enroled at eight major Swiss hospitals and their local affiliated centres, as described previously 16, 34 , and from the Liver Unit of the Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. The study was approved by the Ethics Committee of each SCCS center (Ethikkommission beider Basel EKBB (Basel), Ethikkommission des Kantons St Gallen (St Gallen), Comité intercantonal d'éthique (Neuchâtel), Comité d'éthique du département de Médecine (Geneva), Department Innere Medizin Ethisches Komitee (Zurich), Commission d'éthique de la recherche clinique (Lausanne), Comitato etico cantonale (Lugano)) and by the Ethical committee of 'Casa Sollievo della Sofferenza'. The study included Caucasian patients with spontaneous HCV clearance (defined as presence of anti-HCV antibodies but undetectable HCV RNA without previous antiviral treatment) and those who had chronic infection with HCV genotypes 1, 2, 3 or 4 and were assessable for response to therapy with pegIFNa and ribavirin, that is, who received 480% of the recommended dose of each drug. Polymorphisms in the IFNL3/4 region (rs12979860, rs368234815, rs117648444 and rs8099917) were extracted from a GWAS-generated data set 4 or genotyped by TaqMan (Applied Biosystems, Rotkreuz, Switzerland) or by the Competitive Allele Specific PCR (KASP) system (LGC Genomics, Herts, UK; http://www.lgcgenomics.com/kaspchallenge). Haplotypes were inferred using PHASE software, version 2.1 (University of Washington, available through Express Licensing Program, Seattle, WA, USA; http://stephenslab.uchicago.edu/software.html). Statistical analyses were performed using Stata (version 13.1, StataCorp LP, College Station, TX, USA). LD was assessed using the programs PWLD implemented in Stata. The association of polymorphisms with response to treatment and spontaneous clearance was performed by univariate and multivariate logistic regression. The multivariate models for spontaneous clearance are adjusted for age, sex and HCV risk. The multivariate models for response to treatment are adjusted age, sex, fibrosis stage and viral genotype.
